It is gratifying that acceptable cost-sharing arrangements have, according to published reports, been agreed upon for the next phase of collaborative research, as was the case for the first phase.
Six have income ceilings, with five different formulas for the limits, in each case involving two phase-out schedules, one for single filers and one for joint filers.
However, in the case of Nexavar, Phase III clinical trials with 602 patients showed that it extended the life of the average patient by 2.8 months to 10.7 months, as compared to patients who received a placebo.